ArticleCancer2026
Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChondrosarcoma (CS) has a prognosis largely influenced by tumor grade. Although IDH mutations have been reported in CS, impact on patient`s survival remains controversial. This study aims to assess prognostic relevance of IDH mutations on disease-specific survival (DSS), metastasis-free survival (MFS), and local recurrence-free survival (RFS), in a large cohort of CS patients.
methodsThe authors retrospectively analyzed CS samples from patients treated at two German musculoskeletal tumor centers. Tumor-specific mutations, including IDH, TP53, TERT promoter, and CDKN2A/B, were identified through DNA isolation and next-sequencing. Molecular findings were correlated with oncologic outcomes to evaluate their prognostic significance.
resultsA total of 109 patients (53 females, 56 males; median age, 57 (16-89) years) were included. Tumor grades were G1/ACT (39%), G2 (41%), and G3/dedifferentiated (10%). Median follow-up was 3.8 years with mortality of 17%. IDH mutations were detected in 59% (IDH1: 64%, IDH2: 36%), with dedifferentiated CS showing highest IDH mutation rate (91%), particularly IDH2. IDH2-mutations were associated with significantly worse DSS compared to IDH-wild-type or IDH1-mutated tumors, independent of tumor grade. Specifically, IDH1-R132C mutation correlated with significantly improved DSS compared to R132G, and IDH2-R172S variant showed longest DSS and MFS, whereas IDH2-R172T was linked to significant poor outcomes. In multivariable analysis, IDH2 and TP53 mutations were independent predictors of worse survival.
conclusionIDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision-making in CS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.